Trials / Recruiting
RecruitingNCT05687851
Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer
A Single-arm, Multicenter, Phase II Study to Evaluate Cadonilimab（AK104） Combined With Radiotherapy For The Treatment of Locally Advanced Cervical Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- Sponsor
- Chongqing University Cancer Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Cadonilimab（AK104）is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4. This is a single-arm, multicenter, open-label, phase II study, the purpose of this study is to evaluate the efficacy and safety of Cadonilimab plus radiotherapy in participants with locally advanced cervical cancer who do not tolerate chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cadonilimab（AK104） | q3w iv |
| RADIATION | EBRT | 45-50.4Gy |
| RADIATION | BT | ≥80Gy |
Timeline
- Start date
- 2022-12-29
- Primary completion
- 2024-12-30
- Completion
- 2026-12-01
- First posted
- 2023-01-18
- Last updated
- 2024-09-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05687851. Inclusion in this directory is not an endorsement.